Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Mesenchymal stromal cell therapy is a long-term regenerative approach for chronic radiation cystitis, involving coordinated modulation of the urothelial, immune, vascular, and fibrotic pathways.

Pouliet AL., Côme J., Fail A., Dos Santos M., Linard C., Demarquay C.

Animal Study on Face & Skin, Systemic / IV, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Res Ther (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
42002744
DOI
10.1186/s13287-026-05019-z

Abstract (original English)

Chronic radiation cystitis (CRC) is a disabling late adverse effect of pelvic irradiation, characterized by urothelial barrier loss, persistent inflammation, vascular alteration, and progressive fibrosis. No curative treatment exists. Mesenchymal stromal cells (MSCs) are investigated for their regenerative potential, however their long-term mechanisms of action in CRC remain incompletely elucidated. CRC was induced in rats by localized bladder irradiation (40 Gy). Animals were randomized into unirradiated controls, irradiated controls, and irradiated MSC-treated groups. The treated group received three intravenous injections of adipose-derived MSCs at 4.5, 5.0, and 5.5 months post-irradiation, during the pre-chronic phase. Bladders were analyzed up to 18 months post-irradiation by immunostaining and RT-qPCR for urothelial differentiation (Upk1a, Upk1b, Upk2, Upk3a, Upk3b), epithelial proliferation (CK14⁺/PCNA⁺) and fibrosis (collagen I and III). Immune activation (CD45⁺ leukocytes, neutrophils, mast cells, Gata3, Th1, Th2) was analyzed by flow cytometry and vascular integrity by cystoscopy and Cspg4, VegfA expression. At 18 months post-irradiation, irradiated bladders showed a 90% loss of UPK3 staining and hyperplasia (urothelium thickening) greater than 300 μm result of basal cell hyperproliferation, a ninefold increase compared to controls. MSC treatment reduced hyperplasia b

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsCystitisMesenchymal Stem Cell TransplantationMesenchymal Stem CellsRatsFibrosisUrotheliumMast CellsUrinary BladderFemale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research